StageBio Announces Lori Ball has been appointed as new CEO for StageBio, who brings a history of global leadership in the life sciences industry. Ms Ball will succeed Tom Galati, former CEO and Founder of StageBio, who will remain an integral part of the board of directors. Ms Ball will begin her role January 18, 2022.
In a recent ACT 2021 Talking Tox webinar titled “Safety of E-Cigarette Products – A Toxicological Challenge,” I provided scientific guidance on pathology endpoints for inhalation studies. During my segment, I discussed the special planning necessary to optimize histopathology results when studying test articles dosed via the inhalation route (nose-only, head, or whole-body exposure).
It is with great honor that we introduce Dr. Eric Lee as a Senior Pathologist at StageBio. We are happy to have him on the team and look forward to all he will accomplish!
StageBio’s very own Dr. Thomas Lemarchand will join his colleagues at the 63rd annual American Society of Hematology (ASH) meeting to present their findings on the newly designated Lambda Myeloma Antigen (LMA). During the presentation, which is titled, “A Novel B Cell Antigen Designated Lambda Myeloma Antigen (LMA) Has Been Identified Using Two Fully Human Monoclonal Antibodies (Mabs) That Bind to Similar Epitopes on Plasma Cells from Patients with Plasma Cell Dyscrasias,” Dr. Lemarchand and his team will detail the methods they used to detect the LMA, including flow cytometry on key cell lines and immunohisto-chemistry on normal and pathologic human frozen tissues and results, with what this could mean for myeloma treatment and understanding the pathogenesis.
At StageBio, we’re committed to offering the most reliable and innovative clinical and preclinical services possible. This means not only ensuring we use the most efficient and trusted lab processes available, but also helping our team members to live their best lives—both professionally and personally.
The International Harmonization of Nomenclature and Diagnostic Criteria for Lesions Project (INHAND) has published its overview of nonproliferative and proliferative lesions of the rabbit in the Journal of Toxicologic Pathology. StageBio's senior pathologist, Dr Brett Saladino, is a contributing author to this publication.
We recently hit the webinar stage to give an in-depth look at what it takes to maximize the value of your high-throughput histopathology study. Our goal was to not only outline the basic techniques and philosophy behind histopathology, but to also demystify the entire process.
It is with great honor that we introduce Dr. Lynette Phillips as a Senior Pathologist at StageBio. We are happy to have her on the team and look forward to all she will accomplish!
It is with great honor that we introduce Ailsa Delgado as our Business Development Manager at StageBio. We are happy to have her on the team and look forward to all she will accomplish!
Use Cases and Benefits of Immunohistochemistry, Immunofluorescence, and In Situ Hybridization
Date:
Tuesday, February 1, 2022 @ 1pm – 2pm EST
Location: Virtual
513.204.4400
